Amid uncertainty around federal research funding, universities must explore private support, Purdue University President Mung Chiang told an tech industry group on Tuesday.
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it.
The company said its goal is to reduce wait times for patients seeking access to specialists, creating more opportunities for early diagnosis and intervention.
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
Novo Nordisk’s new offering follows a direct-to-consumer model that Eli Lilly launched last year.
The reductions come at a time of significant growth overall for Lilly. and soon after the announcement of plans to build new manufacturing facilities at four yet-to-be-named U.S. locations.
The LEAP Research and Innovation District, led by the Indiana Economic Development Corp., is among the costliest economic development projects Indiana has attempted. But the agency’s structure obscures its spending and who benefits.
Roughly 16 million people—that’s 6 percent of American adults—are taking GLP-1 weight-loss drugs, and that number is growing rapidly. Their collective purchasing power has the potential to profoundly reshape the economy.
The foundry will give the pharmaceutical maker the ability to research new ways of producing medicines.
President Donald Trump has instructed his administration to scrutinize the “threat” to children posed by antidepressants, stimulants and other common psychiatric drugs.
IMAGE GALLERY: The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians.
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not just for food, but also for tobacco and alcohol.
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.’s Omvoh, a new therapy to treat Chron’s disease and ulcerative colitis, is the company’s latest step into the treatment of gastrointestinal diseases.
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially helping Eli Lilly and Co. and other companies develop new medicines more quickly.
The research is the first to attempt to comprehensively investigate the impact—both good and bad—of the GLP-1 weight-loss drugs on the human body.
The company expects fourth-quarter revenue to be about $13.5 billion.
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.
Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.
The Indiana Family and Social Service Administration’s Office of Medicaid Policy and Planning estimates that 5% to 20% of eligible members would be prescribed weight-loss medications.
The state has spent more than $690 million so far establishing the LEAP Research and Innovation District. Outgoing economic leaders say the project is a huge success, but some political leaders are cautious.
